We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.78B
AUM Growth
+$215M
Cap. Flow
+$34.2M
Cap. Flow %
1.92%
Top 10 Hldgs %
44.5%
Holding
325
New
107
Increased
59
Reduced
54
Closed
92

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$13.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$10.3M
3
OPK icon
Opko Health
OPK
+$7.29M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.72M
5
GILD icon
Gilead Sciences
GILD
+$6.04M

Top Sells

Rank Stock Value
1
MNKD icon
MannKind Corp
MNKD
+$22.4M
2
ABUS icon
Arbutus Biopharma
ABUS
+$9.33M
3
MDVN
MEDIVATION, INC.
MDVN
+$5.53M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$4.82M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.69M

Sector Composition

Rank Sector Weight
1 Miscellaneous 89.24%
2 Healthcare 10.61%
3 Energy 0.15%
4 Communication Services 0%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GSK icon
251
CALL
GSK
GSK
$100B
– –
-5,040
Closed -$33.6M
GSK icon
252
PUT
GSK
GSK
$100B
– –
-70
Closed -$470K
GYRE icon
253
CALL
Gyre Therapeutics
GYRE
$696M
– –
-1
Closed -$187K
GYRE icon
254
Gyre Therapeutics
GYRE
$696M
– –
-45
Closed -$148K
HALO icon
255
CALL
Halozyme
HALO
$12.1B
– –
-700
Closed -$1.05M
IMNN icon
256
CALL
Imunon
IMNN
$8.14M
– –
-2
Closed -$2.33M
INCY icon
257
PUT
Incyte
INCY
$24.5B
– –
-187
Closed -$947K
INVA icon
258
CALL
Innoviva
INVA
$1.5B
– –
-282
Closed -$809K
IONS icon
259
Ionis Pharmaceuticals
IONS
$8.06B
– –
-13,157
Closed -$638K
LLY icon
260
Eli Lilly
LLY
$1.02T
– –
-40,700
Closed -$2.27M
LLY icon
261
PUT
Eli Lilly
LLY
$1.02T
– –
-407
Closed -$2.08M
LXRX icon
262
Lexicon Pharmaceuticals
LXRX
$850M
– –
-142,857
Closed -$1.8M
MBOT icon
263
Microbot Medical
MBOT
$96.7M
– –
-523
Closed -$1.04M
LITS
264
CALL
Lite Strategy Inc
LITS
$37.4M
– –
-14
Closed -$216K
LITS
265
Lite Strategy Inc
LITS
$37.4M
– –
-6,900
Closed -$1.1M
MNKD icon
266
MannKind Corp
MNKD
$1.15B
– –
-786,370
Closed -$22.4M
OEF icon
267
CALL
iShares S&P 100 ETF
OEF
$20.1B
– –
-5,000
Closed -$57.7M
OEF icon
268
PUT
iShares S&P 100 ETF
OEF
$20.1B
– –
-2,000
Closed -$23.1M
PRTA icon
269
Prothena Corp
PRTA
$434M
– –
-19,000
Closed -$613K
RIGL icon
270
Rigel Pharmaceuticals
RIGL
$848M
– –
-76,290
Closed -$2.17M
SPY icon
271
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$798B
– –
-8,933
Closed -$165M
STAA icon
272
CALL
STAAR Surgical
STAA
$1.14B
– –
-676
Closed -$1.09M
STAA icon
273
PUT
STAAR Surgical
STAA
$1.14B
– –
-194
Closed -$314K
TGTX icon
274
TG Therapeutics
TGTX
$8.15B
– –
-66,000
Closed -$257K
VNDA icon
275
Vanda Pharmaceuticals
VNDA
$303M
– –
-146,350
Closed -$1.82M
9 10
11
12 13

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q1 2014 Portfolio in Review

As of Q1 2014, Sabby Management held 325 positions worth $1.78B, up 14% from $1.57B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management's Q1 2014 filing shows 107 new, 59 increased, 54 reduced and 92 closed positions. Its largest new stake was Tenax Therapeutics: 66 shares worth $11.8M. The largest sale was MannKind Corp, an estimated $22.4M.

By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, down from 90% a quarter earlier, followed by Healthcare and Energy.

  • Sabby Management's largest Q1 2014 buy was Tenax Therapeutics: 66 shares worth $11.8M.
  • Sabby Management added most to Gilead Sciences in Q1 2014, an estimated $6.04M increase.
  • Sabby Management's biggest Q1 2014 reduction was Aegerion Pharmaceuticals, cutting an estimated $4.82M.
  • Sabby Management fully exited MannKind Corp in Q1 2014, selling an estimated $22.4M.
  • Sabby Management's ten largest holdings make up 44% of its $1.78B portfolio in Q1 2014.
  • Sabby Management opened 107 new positions and closed 92 in Q1 2014.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $1.78B.

Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.